☆ 4.7 Editorial Material

Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation

CANCER DISCOVERY (2012)

期刊

CANCER DISCOVERY

卷 2, 期 10, 页码 876-880

出版社

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/2159-8290.CD-12-0400

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Signaling pathways and targeted therapies for psoriasis

Jia Guo, Hanyi Zhang, Wenri Lin, Lixia Lu, Juan Su, Xiang Chen

Summary: This review article provides an overview of the epidemiology, clinical subtypes, pathophysiology, and comorbidities of psoriasis. It discusses the signaling pathways, metabolic and epigenetic mechanisms, as well as current treatment options and potential mechanisms of disease recurrence.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunosuppressive Signaling Pathways as Targeted Cancer Therapies

Botle Precious Setlai, Rodney Hull, Meshack Bida, Chrisna Durandt, Thanyani Victor Mulaudzi, Aristotelis Chatziioannou, Zodwa Dlamini

Summary: Immune response is crucial for patient prognosis and response to cancer treatment. Tumors evade immune surveillance by altering antigen processing pathways and the tumor microenvironment. This review highlights the molecular signaling pathways involved in immune suppression and how cancer cells manipulate antigen processing to escape immune surveillance. Additionally, the review explores the potential use of these pathways in precision medicine and understanding drug resistance.

BIOMEDICINES (2022)

添加到收藏夹

Review Oncology

SRC kinase-mediated signaling pathways and targeted therapies in breast cancer

Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Liping Ye, Chengming Zhu, Liang Deng, Bo Wang, Yihang Pan, Peng Li

Summary: Breast cancer is the most common malignant tumor worldwide and a leading cause of cancer-related deaths among women. SRC family kinases (SFKs), a type of non-receptor tyrosine kinase, have been found to play crucial roles in breast cancer progression. This review provides an overview of SRC kinase and its relevant functions in various subtypes of breast cancer, and highlights the role of SRC-mediated substrate phosphorylation in breast cancer signaling transductions. Furthermore, the progress of SRC-based targeted therapies and potential future directions in breast cancer are discussed.

BREAST CANCER RESEARCH (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

Zhenyi Niu, Runsen Jin, Yan Zhang, Hecheng Li

Summary: Lung cancer is a major cause of cancer-related death worldwide, with patients with lung squamous cell carcinoma (LSCC) not benefiting from targeted therapies. Immunotherapy has improved outcomes in cancer patients, but its clinical application in LSCC is hindered by low response rates and adverse events. Understanding the mechanisms of LSCC pathogenesis and the connections between signaling pathways is important for developing more effective treatments. This review discusses classical signaling pathways, potential therapeutic targets, epigenetic and immune checkpoint therapies, and combination strategies for LSCC.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Wnt/β-catenin signaling in cancers and targeted therapies

Fanyuan Yu, Changhao Yu, Feifei Li, Yanqin Zuo, Yitian Wang, Lin Yao, Chenzhou Wu, Chenglin Wang, Ling Ye

Summary: Wnt/β-catenin signaling plays a critical role in human cancers, associated with cancer progression, prognosis, and mortality. Despite the development of therapies targeting this pathway, there are challenges in translating them into clinical practice.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Oncology

Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma

Atreyi Dasgupta, Laura Sierra, Susan Tsang, Lyazat Kurenbekova, Tajhal Patel, Kimal Rajapakshe, Ryan L. Shuck, Nino Rainusso, Yosef Landesman, Thaddeus Unger, Cristian Coarfa, Jason T. Yustein

Summary: The study identifies PAK4 as a novel and viable therapeutic target for high-risk RMS, showing inhibition of PAK4 activity as a promising viable therapeutic option for advanced rhabdomyosarcoma.

CANCER RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

ST6Gal1: Oncogenic signaling pathways and targets

G. C. Sajina, Susan L. L. Bellis, Anita B. Hjelmeland

Summary: The Golgi-sialyltransferase ST6Gal1 plays a role in tumor development and impacts various oncogenic behaviors. However, the signaling pathways and targets regulated by ST6Gal1 are not well-established and require further investigation.

FRONTIERS IN MOLECULAR BIOSCIENCES (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Qian Ding, Wei Hu, Ran Wang, Qinyan Yang, Menglin Zhu, Meng Li, Jianghong Cai, Peter Rose, Jianchun Mao, Yi Zhun Zhu

Summary: Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease that leads to joint deformity and loss of function. In recent decades, researchers have focused on abnormal signaling pathways in RA, providing important evidence for disease understanding and novel intervention targets. This comprehensive review discusses the general overview of RA, including its historical events, epidemiology, risk factors, and pathological process, and highlights the recent progress in identifying signaling pathways and molecular mechanisms, as well as potential therapeutic interventions for RA treatment.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

添加到收藏夹

Review Oncology

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C. Tan, Daniel S. W. Tan

Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Signaling pathways and intervention therapies in sepsis

Yun-yu Zhang, Bo-tao Ning

Summary: Sepsis is a life-threatening organ dysfunction caused by dysregulated host systemic inflammatory and immune response to infection. Advanced understanding of host-microorganism interaction has led to new definitions and therapeutic approaches. Research focus has shifted from pathogenicity of microorganisms to the molecular basis of host responses.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Review Cell Biology

Acylglycerol Kinase-Targeted Therapies in Oncology

Binxiang Chu, Zhenghua Hong, Xiaohe Zheng

Summary: AGK is a recently discovered mitochondrial lipid kinase that plays a crucial role in lipid metabolism stability, mitochondrial protein transport, glycolysis, and thrombocytopoiesis. It has been identified as an oncogene involved in tumor cell growth, invasion, metastasis, and drug resistance, making it a promising target for cancer therapy.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Review Immunology

S-palmitoylation regulates innate immune signaling pathways: molecular mechanisms and targeted therapies

Jing Cai, Jun Cui, Liqiu Wang

Summary: S-palmitoylation is a reversible posttranslational lipid modification that plays a critical role in regulating the biological processes of substrate proteins. This review focuses on the functions of S-palmitoylation in modulating innate immune responses, particularly in the regulation of protein localization, stability, and interactions. The potential and challenges of developing therapies targeting S-palmitoylation or de-palmitoylation for various diseases are also highlighted.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling

Anmol Sharma, Heena Khan, Thakur Gurjeet Singh, Amarjot Kaur Grewal, Agnieszka Najda, Malgorzata Kawecka-Radomska, Mohamed Kamel, Ahmed E. Altyar, Mohamed M. Abdel-Daim

Summary: The ubiquitin-proteasome pathway is crucial in regulating various biological functions and plays a significant role in tumor development. Inhibiting specific enzymes within this pathway can be an effective treatment for cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Biology

Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms

Gary K. L. Chan, Samantha Maisel, Yeonjoo C. Hwang, Bryan C. Pascual, Rebecca R. B. Wolber, Phuong Vu, Krushna C. Patra, Mehdi Bouhaddou, Heidi L. Kenerson, Huat C. Lim, Donald Long, Raymond S. Yeung, Praveen Sethupathy, Danielle L. Swaney, Nevan J. Krogan, Rigney E. Turnham, Kimberly J. Riehle, John D. Scott, Nabeel Bardeesy, John D. Gordan

Summary: Genetic alterations that activate protein kinase A (PKA) are found in many tumor types. The downstream oncogenic signaling mechanisms of PKA activation in human cancer were explored using phosphoproteomics and kinase activity profiling. Two signaling networks, RAS/MAPK components and an AURKA/GSK3 sub-network, were identified, both affecting MYC oncoproteins. Primary mechanism of PKA effects on MYC was found to be translation, which could be blocked with the eIF4A inhibitor zotatifin, suggesting a potential treatment strategy for PKA-driven cancers.

ELIFE (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Deguelin targets multiple oncogenic signaling pathways to combat human malignancies

Hardeep Singh Tuli, Sonam Mittal, Mariam Loka, Vaishali Aggarwal, Diwakar Aggarwal, Akshara Masurkar, Ginpreet Kaur, Mehmet Varol, Katrin Sak, Manoj Kumar, Gautam Sethi, Anupam Bishayee

Summary: Deguelin, a natural rotenoid from plants, has shown promising antineoplastic effects in different cancer subtypes by inhibiting tumor growth and metastasis through various signaling pathways. Initial scientific findings suggest deguelin as a potential anticancer agent for monotherapy or in combination with chemotherapy.

PHARMACOLOGICAL RESEARCH (2021)

添加到收藏夹

Article Genetics & Heredity

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael W. Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra Scherer, Matthew H. Bailey, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Yuanxin Xi, Jing Wang, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Vito W. Rebecca, Hua Sun, R. Jay Mashl, Sherri R. Davies, Ryan Jeon, Christian Frech, Jelena Randjelovic, Jacqueline Rosains, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C. O'Farrell, Elodie Modave, Diether Lambrechts, Petra ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Hyunsoo Kim, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A. Dean, Brandi Davis-Dusenbery, Yvonne A. Evrard, James H. Doroshow, Alana L. Welm, Bryan E. Welm, Michael T. Lewis, Bingliang Fang, Jack A. Roth, Funda Meric-Bernstam, Meenhard Herlyn, Michael A. Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Claudio Isella, Jeffrey A. Moscow, Livio Trusolino, Annette T. Byrne, Jos Jonkers, Carol J. Bult, Enzo Medico, Jeffrey H. Chuang

Summary: The analysis of copy number alterations in patient-derived xenografts (PDXs) and matched patient tumor samples reveals strong conservation of copy number alterations from patient tumors through late-passage PDXs, without systematic evolution driven by the mouse host. This suggests that PDX models are accurate in representing human cancer and that the mouse host does not significantly impact the copy number alterations during tumor evolution within the PDX model.

NATURE GENETICS (2021)

添加到收藏夹

Correction Genetics & Heredity

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (vol 53, pg 86, 2021)

Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael W. Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra Scherer, Matthew H. Bailey, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Yuanxin Xi, Jing Wang, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Vito W. Rebecca, Hua Sun, R. Jay Mashl, Sherri R. Davies, Ryan Jeon, Christian Frech, Jelena Randjelovic, Jacqueline Rosains, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C. O'Farrell, Elodie Modave, Diether Lambrechts, Petra ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Hyunsoo Kim, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A. Dean, Brandi Davis-Dusenbery, Yvonne A. Evrard, James H. Doroshow, Alana L. Welm, Bryan E. Welm, Michael T. Lewis, Bingliang Fang, Jack A. Roth, Funda Meric-Bernstam, Meenhard Herlyn, Michael A. Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Claudio Isella, Jeffrey A. Moscow, Livio Trusolino, Annette T. Byrne, Jos Jonkers, Carol J. Bult, Enzo Medico, Jeffrey H. Chuang

Summary: A correction has been published for this paper.

NATURE GENETICS (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization

Zdenka Dudova, Nathalie Conte, Jeremy Mason, Dalibor Stuchlik, Radim Pesa, Csaba Halmagyi, Zinaida Perova, Abayomi Mosaku, Ross Thorne, Alex Follette, Luboslav Pivarc, Radim Sasinka, Muhammad Usman, Steven Neuhauser, Dale A. Begley, Debra M. Krupke, Massimiliano Frassa, Alessandro Fiori, Riccardo Corsi, Luca Vezzadini, Claudio Isella, Andrea Bertotti, Carol Bult, Helen Parkinson, Enzo Medico, Terrence Meehan, Ales Krenek

Summary: This article introduces the EurOPDX Data Portal, a unified platform that combines the European model catalog and molecular data analysis function. The Portal provides researchers with collaborative research PDX mice models and displays the molecular features and treatment research data of these models.

BMC GENOMICS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Effective drug combinations in breast, colon and pancreatic cancer cells

Patricia Jaaks, Elizabeth A. Coker, Daniel J. Vis, Olivia Edwards, Emma F. Carpenter, Simonetta M. Leto, Lisa Dwane, Francesco Sassi, Howard Lightfoot, Syd Barthorpe, Dieudonne van der Meer, Wanjuan Yang, Alexandra Beck, Tatiana Mironenko, Caitlin Hall, James Hall, Iman Mali, Laura Richardson, Charlotte Tolley, James Morris, Frances Thomas, Ermira Lleshi, Nanne Aben, Cyril H. Benes, Andrea Bertotti, Livio Trusolino, Lodewyk Wessels, Mathew J. Garnett

Summary: Combinations of anti-cancer drugs can overcome resistance and provide new treatments. This study evaluates 2,025 clinically relevant two-drug combinations and finds that synergy between drugs is rare and context-dependent. The findings can guide the development of combination treatments for specific cancer subtypes.

NATURE (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin

Martina Tedesco, Francesca Giannese, Dejan Lazarevic, Valentina Giansanti, Dalia Rosano, Silvia Monzanis, Irene Catalano, Elena Grassi, Eugenia R. Zanella, Oronza A. Botrugno, Leonardo Morelli, Paola Panina Bordignon, Giulio Caravagna, Andrea Bertotti, Gianvito Martino, Luca Aldrighetti, Sebastiano Pasqualato, Livio Trusolino, Davide Cittaro, Giovanni Tonon

Summary: Researchers developed a new single-cell method called scGET-seq to comprehensively study open and closed chromatin and record genomic sequences. They also established Chromatin Velocity, a method to identify trajectories of epigenetic modifications at the single-cell level.

NATURE BIOTECHNOLOGY (2022)

添加到收藏夹

Article Oncology

TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer

Roberto Dinami, Eleonora Petti, Manuela Porru, Angela Rizzo, Federica Ganci, Andrea Sacconi, Paola Ostano, Giovanna Chiorino, Livio Trusolino, Giovanni Blandino, Gennaro Ciliberto, Pasquale Zizza, Annamaria Biroccio

Summary: TRF2, a key protein involved in telomere integrity, has been found to regulate the expression of miRNAs and affect tumor development. The cooperation between TRF2 and CTCF is required for the control of miR-193b-3p expression, which in turn affects tumor cell proliferation and transcription. The association between TRF2 and miR-193b-3p has prognostic value in patients.

CANCER LETTERS (2022)

添加到收藏夹

Article Cell & Tissue Engineering

Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia

Ester Gil Vasquez, Nadia Nasreddin, Gabriel N. Valbuena, Eoghan J. Mulholland, Hayley L. Belnoue-Davis, Holly R. Eggington, Ryan O. Schenck, Valerie M. Wouters, Pratyaksha Wirapati, Kathryn Gilroy, Tamsin R. M. Lannagan, Dustin J. Flanagan, Arafath K. Najumudeen, Sulochana Omwenga, Amy M. B. McCorry, Alistair Easton, Viktor H. Koelzer, James E. East, Dion Morton, Livio Trusolino, Timothy Maughan, Andrew D. Campbell, Maurice B. Loughrey, Philip D. Dunne, Petros Tsantoulis, David J. Huels, Sabine Tejpar, Owen J. Sansom, Simon J. Leedham

Summary: In this study, the distribution of stem cells in intestinal tumors was evaluated and their relationship with epithelial mutation and microenvironmental signaling disruption was explored. The degree of stem cell mixture was found to be closely associated with chemoresistance, and an adaptive equilibrium model was proposed to explain the plasticity of tumor cells.

CELL STEM CELL (2022)

添加到收藏夹

Article Genetics & Heredity

A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells

Mariangela Russo, Simone Pompei, Alberto Sogari, Mattia Corigliano, Giovanni Crisafulli, Alberto Puliafito, Simona Lamba, Jessica Erriquez, Andrea Bertotti, Marco Gherardi, Federica Di Nicolantonio, Alberto Bardelli, Marco Cosentino Lagomarsino

Summary: A study on colorectal cancer cells found that a fraction of persisters replicate slowly, and targeted therapies can induce their transition to drug-tolerant cells with increased mutation rates. Inhibition of error-prone DNA polymerases may be a strategy to restrict tumor recurrence.

NATURE GENETICS (2022)

添加到收藏夹

Review Oncology

Towards precision oncology with patient-derived xenografts

Eugenia R. Zanella, Elena Grassi, Livio Trusolino

Summary: Clinical research requires support from preclinical models that take into consideration the biology and genetics of human cancers, such as patient-derived xenograft (PDX) models. The authors of this Review discuss how PDX models have been used in the past decade for precision oncology and present emerging approaches that could broaden the application of these models.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer

Simonetta M. Leto, Martina Ferri, Francesco Sassi, Eugenia R. Zanella, Francesca Cottino, Valentina Vurchio, Irene Catalano, Alessandro Ferrero, Caterina C. Zingaretti, Caterina Marchio, Elena Grassi, Livio Trusolino, Andrea Bertotti

Summary: In this study, researchers aimed to find rational combinations to enhance the efficacy of the anti-EGFR antibody cetuximab in patients with RAS wild-type metastatic colorectal cancer (mCRC) by disrupting adaptive dependencies on antiapoptotic molecules. Through experiments conducted in patient-derived xenografts (PDX) and organoids (PDXO), they found that concomitant blockade of BCL-XL, an antiapoptotic protein, precipitated cell death and led to more pronounced tumor regressions in combination with cetuximab.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Multidisciplinary Sciences

An mTOR feedback loop mediates the 'flare' ('rebound') response to MET tyrosine kinase inhibition

D. M. Altintas, M. Cerqua, A. De Laurentiis, L. Trusolino, C. Boccaccio, P. M. Comoglio

Summary: Targeted therapy is effective but limited by the 'flare' effect, especially in cancers driven by MET oncogene alterations. Discontinuation of MET tyrosine kinase receptor inhibition leads to a rebound activation of the oncogene, resulting in a dramatic increase in cancer cell proliferation. The molecular mechanisms behind this 'MET burst' after treatment cessation are unknown but crucial for patients.

SCIENTIFIC REPORTS (2023)

添加到收藏夹

Article Cell Biology

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)

Marta Falcinelli, Giulia Dell'Omo, Elena Grassi, Elisa Mariella, Simonetta Maria Leto, Sharon Scardellato, Annalisa Lorenzato, Sabrina Arena, Andrea Bertotti, Livio Trusolino, Alberto Bardelli, Fabrizio d'Adda di Fagagna

Summary: This study found that colorectal cancer (CRC) does not easily engage in alternative lengthening of telomeres (ALT), even with mutations in ATRX and/or DAXX genes.

CELL DEATH & DISEASE (2023)

添加到收藏夹

Article Cell Biology

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

Robin Beekhof, Andrea Bertotti, Franziska Boettger, Valentina Vurchio, Francesca Cottino, Eugenia R. Zanella, Giorgia Migliardi, Marco Viviani, Elena Grassi, Barbara Lupo, Alex A. Henneman, Jaco C. Knol, Thang V. Pham, Richard de Goeij-de Haas, Sander R. Piersma, Mariette Labots, Henk M. W. Verheul, Livio Trusolino, Connie R. Jimenez

Summary: This study used proteomics and phosphoproteomics to investigate the molecular basis of response to EGFR blockade in metastatic colorectal cancer (mCRC). The research found distinctive response signatures in the proteome and phosphoproteome, with sensitive tumors showing increased pathway activity related to MAPK inhibition and abundant tyrosine phosphorylation of cell junction proteins, while resistant tumors exhibited epithelial-mesenchymal transition and increased MAPK and AKT signaling. The analysis also revealed high kinase activity of ERBB2, EGFR, MET, Src, and ephrin kinase family members in cetuximab-resistant tumors. Inhibition of these hyperactive kinases resulted in growth inhibition of ex vivo and in vivo models. These findings highlight the potential value of phosphoproteomics in improving our understanding of anti-EGFR treatment and response prediction in mCRC, and identifying alternative drug targets in cetuximab-resistant tumors.

SCIENCE TRANSLATIONAL MEDICINE (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.